Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01375140 · ClinicalTrials.gov registry record · Phase 2
Ruxolitinib and Lenalidomide for Patients With Myelofibrosis
A Phase 2 study, sponsored by M.D. Anderson Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
- 31
- Enrollment target
NCT01375140: Completed Phase 2 study, sponsored by M.D. Anderson Cancer Center.
NCT01375140 is a Phase 2 study that has completed, run by M.D. Anderson Cancer Center. The registered enrollment target is 31 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01375140, a Phase 2 study, has completed, sponsored by M.D. Anderson Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 31 participants
- Enrollment target
Study Summary
The goal of this clinical research study is to learn if the combination of ruxolitinib and lenalidomide can help to control MF. The safety of this study drug combination will also be studied. Ruxolitinib is designed to stop certain proteins (called JAK1 and JAK2) that are found in MF cells from sending signals that may lead to the growth of cancer cells. Lenalidomide is designed to change the body's immune system. It may also interfere with the development of tiny blood vessels that help support tumor growth. This may decrease the growth of cancer cells.
Interventions
- DRUG Lenalidomide
- DRUG Prednisone
- DRUG Ruxolitinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 31 participants |
| Start Date | 2011-09-22 |
| Est. Completion | 2018-09-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01375140
The ClinicalTrials.gov registry entry for NCT01375140 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 31 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is M.D. Anderson Cancer Center, which has 2,692 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Lenalidomide is the first listed.
NCT01375140 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01375140 about?
NCT01375140 is a clinical study titled "Ruxolitinib and Lenalidomide for Patients With Myelofibrosis". The goal of this clinical research study is to learn if the combination of ruxolitinib and lenalidomide can help to control MF. The safety of this study drug combination will also be studied. Ruxolitinib is designed to stop certain proteins (called JAK1 and JAK2) that are found in MF cells from sen...
What is the current status of trial NCT01375140?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 31 participants. The study started on 2011-09-22. Estimated completion is 2018-09-05.
What interventions are being tested in trial NCT01375140?
The interventions under investigation include: Lenalidomide (DRUG), Prednisone (DRUG), Ruxolitinib (DRUG).
Who is sponsoring clinical trial NCT01375140?
This trial is sponsored by M.D. Anderson Cancer Center, which has 2,692 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.